Publications
Publications
Show Results For
- All HBS Web
(1,020)
- Faculty Publications (263)
Drug
→
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca Henderson and Iain Cockburn
- December 2000
- Case
Drug Wars, The: Pfizer's Hostile Bid for Warner-Lambert in 1999
By: Stephen P. Bradley and Matthew Sandoval
Describes Pfizer's hostile bid for Warner-Lambert in the fall of 1999. Allows for an evaluation of the possible synergies created and poses the question as to whether Pfizer will pay too much. View Details
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
- 2000
- Chapter
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
- July – August 2000
- Article
Drug Industry Mergers Won't Necessarily Benefit R&D
- 1996
- Chapter
Eli Lilly and Company: Drug Development Strategy
By: S. Thomke, A. Nimgade and P. Pospisil
- February 2000 (Revised October 2000)
- Case
Kendle International Inc.
By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details
- Article
Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting
By: J. H. Gurwitz, T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson and D. W. Bates
- December 1999 (Revised August 2001)
- Case
Millennium Pharmaceuticals, Inc. (A)
By: Stefan H. Thomke and Ashok Nimgade
Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details
- December 1999 (Revised February 2001)
- Case
CVS: The Web Strategy
By: John A. Deighton and Anjali C. Shah
How should America's second-largest pharmacy chain respond to the challenge from online drugstores? What threat does the web pose to bricks and mortar distribution of prescription drugs and the other items that make up 50% of a drugstore's sales? This case describes... View Details
- June 1999 (Revised October 1999)
- Case
Eli Lilly, 1998 (A): Strategic Challenges
By: Michael Y. Yoshino and Thomas W. Malnight
Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details
- June 1999 (Revised June 2000)
- Case
Eckerd Corporation
By: Michael E. Porter and John E. Kelleher
Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details
- March 1999 (Revised June 2000)
- Case
Eli Lilly: The Evista Project
By: Steven C. Wheelwright and Matt Verlinden
Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)... View Details
- January 1999
- Background Note
Note on the Drugstore Industry
By: David E. Bell and Ann Leamon
In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details
- Article
Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
- May 1998
- Background Note
Pharma Giants,The: Ready for the 21st Century?
By: Robert H. Hayes and Perry Fagan
Presents the changing competitive dynamics in the global pharmaceutical industry and possible implications for large drug companies. View Details
- April 1998
- Case
Cephalon, Inc.
By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details